Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Sidewinder Therapeutics has secured $137m in a Series B financing round to progress its pipeline of bispecific antibody-drug conjugates (ADCs) …
Post
-
-
RoosterBio and MineBio team up to expand MSC solutions access in China
RoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to scalable, research-grade and current good …
-
Pharma industry laments Trump’s tariff on branded drugs
The pharmaceutical industry has widely criticised the US administration’s decision to impose a 100% tariff on branded drugs imported into …
-
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's …
-
Why Timelines Break Down in Rare Kidney Drug Development
Enrollment challenges continue to be a defining constraint in nephrology research. In a January 2026 snapshot of GlobalData’s clinical trial …
-
Gilead outlays $5bn to acquire ADC specialist Tubulis
Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company’s …
-
In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe
Last year saw the largest fall in US contract manufacturing (CM) deals for FDA-approved drugs in five years. Despite the …
-
Apnimed obtains up to $150m in funds for commercial launch of AD109
Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) …
-
The hidden bottleneck in digital healthcare: Why hospital wireless networks are under pressure in 2026
Healthcare is entering a new era of digital transformation. In the US, competition among leading providers is driving rapid adoption …
-
The evolving landscape of subcutaneous drug administration
In pharmaceutical development, several major trends are shaping the future of drug delivery. For decades now, the industry has been …
-
CGT’s next obstacle: Securing the leukapheresis supply chain
Clinical trial numbers for CAR-T therapies have risen dramatically in recent years, and as these programmes expand beyond oncology into …
-
Neurocrine to acquire Soleno in $2.9bn transaction
Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn …
-
Aspect Biosystems receives funding for cellular medicine project
Aspect Biosystems has secured a C$79m($56.6m) investment from the Government of Canada to support a C$280m multi-year project aimed at …
-
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer
Merck (MSD) has received the European Commission (EC) approval for Keytruda (pembrolizumab) along with paclitaxel, with or without bevacizumab, as …
-
HNSCC market is expected to reach to $4.5bn across 8MM by 2034
GlobalData anticipates notable growth in the head and neck squamous cell carcinoma (HNSCC) therapeutics market across the eight major markets …
